GSK vs. ONC: A Head-to-Head Stock Comparison

Updated on October 4, 2025

Here’s a clear look at GSK and ONC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Both GSK and ONC are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.

Symbol	GSK	ONC
Company Name	GSK plc	BeOne Medicines AG
Country	United Kingdom	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry	Pharmaceuticals	Biotechnology
Market Capitalization	91.59 billion USD	37.96 billion USD
Exchange	NYSE	NasdaqGS
Listing Date	March 28, 1980	February 3, 2016
Security Type	ADR	ADR

Historical Performance

This chart compares the performance of GSK and ONC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

GSK vs. ONC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	GSK	ONC
5-Day Price Return	6.03%	-0.90%
13-Week Price Return	11.47%	32.50%
26-Week Price Return	6.71%	41.02%
52-Week Price Return	5.28%	20.61%
Month-to-Date Return	8.40%	10.40%
Year-to-Date Return	16.93%	90.60%
10-Day Avg. Volume	5.46M	4.56M
3-Month Avg. Volume	5.70M	4.05M
3-Month Volatility	24.21%	51.09%
Beta	0.99	0.78

Profitability

Return on Equity (TTM)

GSK

24.18%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.85%
Q1: 5.40%
Min: -10.91%

In the upper quartile for the Pharmaceuticals industry, GSK’s Return on Equity of 24.18% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

ONC

-6.58%

Biotechnology Industry

Max: 97.92%
Q3: 11.99%
Median: -19.30%
Q1: -51.29%
Min: -132.03%

ONC has a negative Return on Equity of -6.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

GSK vs. ONC: A comparison of their Return on Equity (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Net Profit Margin (TTM)

GSK

10.82%

Pharmaceuticals Industry

Max: 40.67%
Q3: 19.07%
Median: 12.31%
Q1: 4.50%
Min: -9.91%

GSK’s Net Profit Margin of 10.82% is aligned with the median group of its peers in the Pharmaceuticals industry. This indicates its ability to convert revenue into profit is typical for the sector.

ONC

-5.04%

Biotechnology Industry

Max: 73.34%
Q3: 18.98%
Median: -12.96%
Q1: -105.72%
Min: -259.82%

ONC has a negative Net Profit Margin of -5.04%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

GSK vs. ONC: A comparison of their Net Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Operating Profit Margin (TTM)

GSK

16.22%

Pharmaceuticals Industry

Max: 45.78%
Q3: 23.14%
Median: 16.68%
Q1: 7.98%
Min: -7.13%

GSK’s Operating Profit Margin of 16.22% is around the midpoint for the Pharmaceuticals industry, indicating that its efficiency in managing core business operations is typical for the sector.

ONC

-2.03%

Biotechnology Industry

Max: 78.85%
Q3: 21.90%
Median: -13.30%
Q1: -109.94%
Min: -278.10%

ONC has a negative Operating Profit Margin of -2.03%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

GSK vs. ONC: A comparison of their Operating Profit Margin (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Profitability at a Glance

Symbol	GSK	ONC
Return on Equity (TTM)	24.18%	-6.58%
Return on Assets (TTM)	5.77%	-3.87%
Net Profit Margin (TTM)	10.82%	-5.04%
Operating Profit Margin (TTM)	16.22%	-2.03%
Gross Profit Margin (TTM)	71.77%	85.37%

Financial Strength

Current Ratio (MRQ)

GSK

0.87

Pharmaceuticals Industry

Max: 4.65
Q3: 2.64
Median: 1.85
Q1: 1.26
Min: 0.78

GSK’s Current Ratio of 0.87 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ONC

1.94

Biotechnology Industry

Max: 16.97
Q3: 8.39
Median: 4.11
Q1: 2.64
Min: 0.74

ONC’s Current Ratio of 1.94 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

GSK vs. ONC: A comparison of their Current Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Debt-to-Equity Ratio (MRQ)

GSK

1.17

Pharmaceuticals Industry

Max: 1.75
Q3: 0.82
Median: 0.35
Q1: 0.13
Min: 0.00

GSK’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 1.17. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.

ONC

0.27

Biotechnology Industry

Max: 1.92
Q3: 0.79
Median: 0.12
Q1: 0.00
Min: 0.00

ONC’s Debt-to-Equity Ratio of 0.27 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

GSK vs. ONC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Interest Coverage Ratio (TTM)

GSK

2.37

Pharmaceuticals Industry

Max: 103.95
Q3: 43.60
Median: 9.83
Q1: 2.37
Min: -42.71

GSK’s Interest Coverage Ratio of 2.37 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

ONC

-132.16

Biotechnology Industry

Max: 72.37
Q3: 1.03
Median: -9.59
Q1: -65.05
Min: -163.11

ONC has a negative Interest Coverage Ratio of -132.16. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

GSK vs. ONC: A comparison of their Interest Coverage Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Financial Strength at a Glance

Symbol	GSK	ONC
Current Ratio (MRQ)	0.87	1.94
Quick Ratio (MRQ)	0.57	1.65
Debt-to-Equity Ratio (MRQ)	1.17	0.27
Interest Coverage Ratio (TTM)	2.37	-132.16

Growth

Revenue Growth

GSK vs. ONC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

GSK vs. ONC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

GSK

3.93%

Pharmaceuticals Industry

Max: 7.14%
Q3: 3.45%
Median: 2.17%
Q1: 0.33%
Min: 0.00%

With a Dividend Yield of 3.93%, GSK offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.

ONC

0.17%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC’s Dividend Yield of 0.17% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

GSK vs. ONC: A comparison of their Dividend Yield (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend Payout Ratio (TTM)

GSK

54.01%

Pharmaceuticals Industry

Max: 199.58%
Q3: 97.17%
Median: 53.47%
Q1: 22.97%
Min: 0.00%

GSK’s Dividend Payout Ratio of 54.01% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ONC

0.00%

Biotechnology Industry

Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ONC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

GSK vs. ONC: A comparison of their Dividend Payout Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Dividend at a Glance

Symbol	GSK	ONC
Dividend Yield (TTM)	3.93%	0.17%
Dividend Payout Ratio (TTM)	54.01%	0.00%

Valuation

Price-to-Earnings Ratio (TTM)

GSK

18.51

Pharmaceuticals Industry

Max: 45.19
Q3: 27.91
Median: 20.59
Q1: 15.08
Min: 3.79

GSK’s P/E Ratio of 18.51 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ONC

Biotechnology Industry

Max: 40.44
Q3: 39.37
Median: 22.12
Q1: 15.76
Min: 3.48

P/E Ratio data for ONC is currently unavailable.

GSK vs. ONC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Sales Ratio (TTM)

GSK

2.00

Pharmaceuticals Industry

Max: 8.87
Q3: 4.56
Median: 2.14
Q1: 1.58
Min: 0.11

GSK’s P/S Ratio of 2.00 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ONC

9.25

Biotechnology Industry

Max: 92.67
Q3: 41.36
Median: 8.45
Q1: 4.46
Min: 0.97

ONC’s P/S Ratio of 9.25 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

GSK vs. ONC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Price-to-Book Ratio (MRQ)

GSK

3.84

Pharmaceuticals Industry

Max: 9.78
Q3: 4.99
Median: 2.48
Q1: 1.53
Min: 0.59

GSK’s P/B Ratio of 3.84 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

ONC

8.16

Biotechnology Industry

Max: 22.72
Q3: 10.68
Median: 4.55
Q1: 2.44
Min: 0.59

ONC’s P/B Ratio of 8.16 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

GSK vs. ONC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Pharmaceuticals and Biotechnology industry benchmarks.

Valuation at a Glance

Symbol	GSK	ONC
Price-to-Earnings Ratio (TTM)	18.51	--
Price-to-Sales Ratio (TTM)	2.00	9.25
Price-to-Book Ratio (MRQ)	3.84	8.16
Price-to-Free Cash Flow Ratio (TTM)	13.58	156.50